Welcome to our dedicated page for Adial Pharmaceuticals SEC filings (Ticker: ADIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Adial Pharmaceuticals’ dense biotech disclosures can feel like navigating a clinical protocol—hundreds of pages on trial endpoints, FDA feedback, and financing terms. Yet missing a single footnote on AD04’s pivotal study or an executive’s stock sale could change your thesis overnight.
Stock Titan solves this problem. Our AI-powered engine delivers Adial Pharmaceuticals SEC filings explained simply, pulling key data from every submission the moment it hits EDGAR. Whether you need the latest Adial Pharmaceuticals quarterly earnings report 10-Q filing, an Adial Pharmaceuticals 8-K material events explained, or a full Adial Pharmaceuticals annual report 10-K simplified, you’ll get concise summaries, red-flag highlights, and side-by-side comparisons—no scientific dictionary required.
Have specific questions? Ask them naturally: “How is the cash runway after Phase III?” or “Show me Adial Pharmaceuticals insider trading Form 4 transactions.” Our platform surfaces Adial Pharmaceuticals Form 4 insider transactions real-time, tracks Adial Pharmaceuticals executive stock transactions Form 4, and links them to catalyst dates. Dive deeper with AI-driven Adial Pharmaceuticals earnings report filing analysis, parse the Adial Pharmaceuticals proxy statement executive compensation, or benchmark risk factors across quarters—all in one place.
- Monitor trial milestones inside 10-K, 10-Q and 8-K forms
- Spot insider sentiment before material announcements
- Compare R&D spend and dilution scenarios instantly
- Export data to your models for evidence-based decisions
Stop wading through PDFs. Start understanding Adial Pharmaceuticals SEC documents with AI—complete coverage, real-time alerts, and insights that let you focus on investment strategy, not document hunting.
Adial Pharmaceuticals has scheduled its 2025 Annual Meeting for August 1, 2025, with several significant proposals up for stockholder vote. Key proposals include:
- Election of two Class I directors for three-year terms
- Approval to issue up to 6.7 million shares for May 2025 warrant exercises and 19.4 million shares for June 2025 warrant exercises
- Implementation of a reverse stock split at a ratio between 1-for-2 and 1-for-25
- Increase in authorized common stock from 50 million to 100 million shares
- Expansion of 2017 Equity Incentive Plan share pool from 2 million to 5 million shares
The meeting will be held at Charlottesville, Virginia. CBIZ CPAs P.C. to be ratified as independent auditor. The record date is June 4, 2025. The proposals reflect significant corporate restructuring efforts, including potential share dilution and capital structure changes that could materially impact stockholders.
Adial Pharmaceuticals, Inc. (ADIL) reported the completion of a best-efforts public offering on 18 June 2025 that generated gross proceeds of approximately $3.6 million. The transaction combined newly issued common shares, pre-funded warrants and two new warrant series, materially increasing the company’s potential fully-diluted share count.
Key terms of the offering
- 5,341,200 new common shares and 5,758,800 pre-funded warrants were sold. Each share or pre-funded warrant unit was paired with one Series D and one Series E warrant.
- Pricing: $0.3251 per common share unit; $0.3241 per pre-funded unit.
- Aggregate securities created: up to 11,100,000 Series D warrant shares (exercise price $0.35; 5-year life) and 8,325,000 Series E warrant shares (exercise price $0.35; 18-month life).
- Pre-funded warrants have a de minimis $0.001 exercise price and no expiration; all warrants include customary anti-dilution and cashless-exercise features and a 4.99%/9.99% ownership cap.
- The securities were registered on Form S-1 (File No. 333-287826) declared effective 16 June 2025.
Use of proceeds: The company intends to deploy the net funds for working capital and general corporate purposes.
Placement & lock-ups: A.G.P./Alliance Global Partners acted as exclusive placement agent, earning 7.0 % of gross proceeds (less a 3.5 % credit on tail-list investors) plus a 1.0 % management fee and up to $75,000 in expense reimbursement. The purchase and placement agreements restrict additional equity issuances for 30 days (general) and 60 days (ATM/variable rate), with limited exceptions.
Warrant amendments: Concurrently, the exercise price on existing Series B-1 (2,482,270 shares) and Series C-1 (4,025,000 shares) warrants was reduced to $0.35. Expirations were extended to 17 Jun 2030 (B-1) and 17 Dec 2026 (C-1), subject to future shareholder approval obligations.
Investor impact
- The raise strengthens near-term liquidity but is modest relative to the potential issuance of up to 30 million additional shares, implying significant dilution.
- Common warrant exercise is conditional on shareholder approval to be secured within 120 days; failure to obtain approval could delay additional dilution or cash inflow.
- The repricing and term extension of prior warrants increases the likelihood of further share issuance at $0.35.
Overall, the 8-K details substantial low-priced equity and warrant issuance that improves cash resources but materially increases future dilution risk.
FAQ
What is the current stock price of Adial Pharmaceuticals (ADIL)?
What is the market cap of Adial Pharmaceuticals (ADIL)?
What is the core focus of Adial Pharmaceuticals?
How does AD04 work?
What differentiates Adial from other pharmaceutical companies in the addiction treatment space?
How does Adial leverage pharmacogenomics in its treatment approach?
What therapeutic areas does Adial focus on?
What is the significance of the 505(b)(2) regulatory pathway for Adial?
How does Adial ensure the safety and efficacy of its investigational products?
How is Adial building its competitive advantage?
